Hersha Hospitality Trust
Change company Symbol lookup
Select an option...
HT Hersha Hospitality Trust
MFA MFA Financial Inc
TUES Tuesday Morning Corp
LXXGF Lexagene Holdings Inc
BKE Buckle Inc
CRMT America's CAR-MART Inc
DE Deere & Co
JKS JinkoSolar Holding Co Ltd
TLGT Teligent Inc (NEW JERSEY)
ALK Alaska Air Group Inc

Real Estate : Equity Real Estate Investment Trusts (REITs) | Small Cap Value
Company profile

Hersha Hospitality Trust is a self-advised real estate investment trust (REIT). The Company invests primarily in institutional grade hotels in urban gateway markets, including New York, Washington, District of Columbia, Boston, Philadelphia, South Florida and select markets on the West Coast. As of December 31, 2017, the Company's hotels included 50 hotels totaling 7,725 rooms located in New York, Washington, DC, Boston, Philadelphia, South Florida and select markets on the West Coast. The Company’s properties operate under brands that include Marriott International, Hilton Hotels, Hyatt Hotels, Intercontinental Hotel Group, and Pan Pacific.

Closing Price
Day's Change
-0.11 (-2.29%)
B/A Size
Day's High
Day's Low

10-day average volume:

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences

6:50 pm ET March 19, 2020 (PR Newswire) Print

Danaher Corporation (NYSE: DHR) ("Danaher") announced today that the U.S. Federal Trade Commission (the "FTC") has accepted the proposed consent order in connection with Danaher's definitive agreement with General Electric Company ("GE") (NYSE: GE) to acquire the Biopharma business of GE Life Sciences ("GE Biopharma").

The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained for the acquisition of GE Biopharma by Danaher. In addition to the FTC, the transaction has also been cleared by the European Commission and the Brazilian, Chinese, Israeli, Japanese, Korean and Russian antitrust authorities. The closing of the acquisition remains subject to other customary closing conditions set forth in the purchase agreement. Danaher currently expects that the acquisition will be completed on March 31, 2020.

ABOUT DANAHERDanaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of more than 60,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.

FORWARD-LOOKING STATEMENTSStatements in this release that are not strictly historical, including the statements regarding the anticipated acquisition of GE Biopharma and the timing thereof and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the parties' ability to satisfy the remaining acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2019 Annual Report on Form 10-K. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.


View original content:http://www.prnewswire.com/news-releases/danaher-receives-clearance-from-us-federal-trade-commission-for-the-acquisition-of-the-biopharma-business-of-general-electric-life-sciences-301027237.html

SOURCE Danaher Corporation


Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.